These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1979215)

  • 1. Receptor pharmacology of MDMA and related hallucinogens.
    Teitler M; Leonhardt S; Appel NM; De Souza EB; Glennon RA
    Ann N Y Acad Sci; 1990; 600():626-38; discussion 638-9. PubMed ID: 1979215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs.
    Sanders-Bush E; Breeding M
    Psychopharmacology (Berl); 1991; 105(3):340-6. PubMed ID: 1665919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.
    Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1988 Sep; 246(3):866-70. PubMed ID: 2901488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination.
    Baker LE; Taylor MM
    Pharmacol Biochem Behav; 1997 Aug; 57(4):737-48. PubMed ID: 9259001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonergic mechanisms of hallucinogenic drug effects.
    Heym J; Jacobs BL
    Monogr Neural Sci; 1987; 13():55-81. PubMed ID: 2891030
    [No Abstract]   [Full Text] [Related]  

  • 6. Hallucinogenic and stimulatory amphetamine derivatives: fingerprinting DOM, DOI, DOB, MDMA, and MBDB by spectral analysis of brain field potentials in the freely moving rat (Tele-Stereo-EEG).
    Dimpfel W; Spüler M; Nichols DE
    Psychopharmacology (Berl); 1989; 98(3):297-303. PubMed ID: 2568652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis.
    Sadzot B; Baraban JM; Glennon RA; Lyon RA; Leonhardt S; Jan CR; Titeler M
    Psychopharmacology (Berl); 1989; 98(4):495-9. PubMed ID: 2505289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug discrimination studies with MDMA and amphetamine.
    Oberlender R; Nichols DE
    Psychopharmacology (Berl); 1988; 95(1):71-6. PubMed ID: 2898791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens.
    Titeler M; Lyon RA; Glennon RA
    Psychopharmacology (Berl); 1988; 94(2):213-6. PubMed ID: 3127847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors.
    Leonhardt S; Gorospe E; Hoffman BJ; Teitler M
    Mol Pharmacol; 1992 Aug; 42(2):328-35. PubMed ID: 1355262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MDMA-like stimulus effects of alpha-ethyltryptamine and the alpha-ethyl homolog of DOM.
    Glennon RA
    Pharmacol Biochem Behav; 1993 Oct; 46(2):459-62. PubMed ID: 7903460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3,4-Methylenedioxymethamphetamine (MDMA): stereoselective interactions at brain 5-HT1 and 5-HT2 receptors.
    Lyon RA; Glennon RA; Titeler M
    Psychopharmacology (Berl); 1986; 88(4):525-6. PubMed ID: 2871581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-[125I]iodo-(2,5-dimethoxy)phenylisopropylamine and [3H]ketanserin labeling of 5-hydroxytryptamine2 (5HT2) receptors in mammalian cells transfected with a rat 5HT2 cDNA: evidence for multiple states and not multiple 5HT2 receptor subtypes.
    Teitler M; Leonhardt S; Weisberg EL; Hoffman BJ
    Mol Pharmacol; 1990 Nov; 38(5):594-8. PubMed ID: 2233696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abuse potential of methylenedioxymethamphetamine (MDMA) and its derivatives in zebrafish: role of serotonin 5HT2-type receptors.
    Ponzoni L; Braida D; Sala M
    Psychopharmacology (Berl); 2016 Aug; 233(15-16):3031-9. PubMed ID: 27318987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity.
    Oberlender R; Nichols DE
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1098-106. PubMed ID: 1979813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin2 agonist administration down-regulates rat brain serotonin2 receptors.
    Buckholtz NS; Zhou DF; Freedman DX
    Life Sci; 1988; 42(24):2439-45. PubMed ID: 3374263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (+)Lysergic acid diethylamide, but not its nonhallucinogenic congeners, is a potent serotonin 5HT1C receptor agonist.
    Burris KD; Breeding M; Sanders-Bush E
    J Pharmacol Exp Ther; 1991 Sep; 258(3):891-6. PubMed ID: 1679849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors.
    Lyon RA; Davis KH; Titeler M
    Mol Pharmacol; 1987 Feb; 31(2):194-9. PubMed ID: 3543649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (R)-(-)-[77Br]4-bromo-2,5-dimethoxyamphetamine labels a novel 5-hydroxytryptamine binding site in brain membranes.
    Peroutka SJ; Hamik A; Harrington MA; Hoffman AJ; Mathis CA; Pierce PA; Wang SS
    Mol Pharmacol; 1988 Oct; 34(4):537-42. PubMed ID: 3173334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychostimulant properties of MDMA.
    Gold LH; Geyer MA; Koob GF
    NIDA Res Monogr; 1989; 95():345-6. PubMed ID: 2577038
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.